ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Immunological Complications of Medical Therapy Poster

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM
Abstract Number: 0752
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis
9:00AM-10:30AM
Abstract Number: 0773
Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease
9:00AM-10:30AM
Abstract Number: 0767
Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies
9:00AM-10:30AM
Abstract Number: 0766
CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0776
Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
9:00AM-10:30AM
Abstract Number: 0769
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 0774
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
9:00AM-10:30AM
Abstract Number: 0753
Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
9:00AM-10:30AM
Abstract Number: 0761
Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
9:00AM-10:30AM
Abstract Number: 0777
Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study
9:00AM-10:30AM
Abstract Number: 0770
Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies
9:00AM-10:30AM
Abstract Number: 0755
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
9:00AM-10:30AM
Abstract Number: 0763
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
9:00AM-10:30AM
Abstract Number: 0759
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
9:00AM-10:30AM
Abstract Number: 0772
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
9:00AM-10:30AM
Abstract Number: 0764
No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
9:00AM-10:30AM
Abstract Number: 0754
Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
9:00AM-10:30AM
Abstract Number: 0760
Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors
9:00AM-10:30AM
Abstract Number: 0768
Reevaluating Clinical Outcomes of Patients on Combination Biologics
9:00AM-10:30AM
Abstract Number: 0758
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
9:00AM-10:30AM
Abstract Number: 0756
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
9:00AM-10:30AM
Abstract Number: 0762
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
9:00AM-10:30AM
Abstract Number: 0757
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
9:00AM-10:30AM
Abstract Number: 0775
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
9:00AM-10:30AM
Abstract Number: 0765
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
9:00AM-10:30AM
Abstract Number: 0771
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
9:00AM-10:30AM
Abstract Number: 0778
TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology